Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma

Table 1 Baseline characteristics of the patients (n = 187)

Sex (male/female), n (%)	95 (50.8%)/92 (49.2%)
Age (yr), mean ± SD	53.7 ± 15.2
HBV/HCV/PBC/AIH/ALD, n	72/75/22/7/11
Duration of follow-up (mo), median (IQR)	96.5 (102)
INR, median (IQR), (normal range: 0.85-1.15)	1.04 (0.24)
Platelets (× 103/μL), median (IQR), (normal range: 140-440)	190 (116)
AST (U/L), median (IQR), (UNL: 40 U/L)	38 (45)
ALT (U/L), median (IQR), (UNL: 40 U/L)	40 (46)
γ-GT (U/L), median (IQR), (UNL: 37 U/L)	33 (52)
ALP (U/L), median (IQR), (UNL: 104 U/L)	90 (74)
Bilirubin (mg/dL), median (IQR), (UNL: 1.1 mg/dL)	0.8 (0.8)
Albumin (g/dL), median (IQR), (normal range: 3.5-5.2 g/dL)	4.3 (1.0)
IgG (mg/dL), mean ± SD, (UNL: 1650 mg/dL)	1583 ± 508
IgM (mg/dL), median (IQR), (UNL: 200 mg/dL)	135 (147)
IgA (mg/dL), mean ± SD, (UNL: 300 mg/dL)	312 ± 192
AFP (ng/mL), median (IQR), (UNL: 10 ng/mL)	4.6 (6.4)
Cirrhosis (yes/no), n (%)	98 (52.4%)/89 (47.6%)
Decompensation of cirrhosis1 (yes/no), n (%)	27 (27.6%)/71 (72.4%)
HCC (yes/no), n (%)	12 (6.4%)/175 (93.6%)
Histological grade (none/minimal/mild vs moderate/severe), n (%)	61 (55.5%)/49 (44.5%)
Histological stage (none/minimal/mild vs moderate/severe/cirrhosis), n (%)	62 (56.4%)/48 (43.6%)

¹Decompensation of cirrhosis denotes the development of at least one of the following: variceal bleeding, hepatic encephalopathy or ascites. n: Number of patients in each respective group; SD: Standard deviation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PBC: Primary biliary cirrhosis; AIH: Autoimmune hepatitis; ALD: Alcoholic liver disease; INR: International normalized ratio; AST: Aspartate aminotransferase; UNL: Upper normal limit; ALT: Alanine aminotransferase; γ-GT: γ-glutamyl transpeptidase; ALP: Alkaline phosphatase; IgG: Immunoglobulin G; IgM: Immunoglobulin M; IgA: Immunoglobulin A; AFP: Alpha fetoprotein; HCC: Hepatocellular carcinoma.